,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec 2022', 'fs': 'Dec 2022', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000009MNVe2AO'}, 'Id': 'a0POZ000009MNVe2AO', 'Event_Date__c': '2022-12-16', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Dec 2022', 'Status_History__c': 'a132P000000EDCcQAO'}, 'change': None}]",Dec 2022,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec 2022', 'fs': 'Dec 2022', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000009MNVf2AO'}, 'Id': 'a0POZ000009MNVf2AO', 'Event_Date__c': '2022-12-16', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Dec 2022', 'Status_History__c': 'a132P000000EDCmQAO'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec 2022', 'fs': 'Dec 2022', 'change': None}, 'Event_Description': {'s': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Friday 17 February 2023', 'fs': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Friday 17 February 2023', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000009MNVg2AO'}, 'Id': 'a0POZ000009MNVg2AO', 'Event_Date__c': '2022-12-16', 'Event_Description__c': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Friday 17 February 2023', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Dec 2022', 'Status_History__c': 'a132P000000EDD2QAO'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee <strong>recommended</strong> widening access to Ustekinumab<span style=""color: gray;""> </span>to first-line biologic use for those with Crohn’s disease or ulcerative colitis with a <strong>low priority </strong>subject to the following Special Authority criteria<strong>:</strong>\xa0</p><p><br></p><p><strong style=""font-size: 11px;"">USTEKINUMAB</strong></p><p><span style=""font-size: 11px;"">\t</span><strong style=""font-size: 11px;"">Initiation –Crohn’s disease- adult</strong></p><p><span style=""font-size: 11px;"">\tApplications only from a relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 11px;"">\tAll of the following:</span></p><p><span style=""font-size: 11px;"">\t1.\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0Individual has active Crohn’s disease; and </span></p><p><span style=""font-size: 11px;"">\t2.\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0Any of the following: </span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">2.1.\xa0\xa0\xa0\xa0\xa0Patient has Crohn’s disease active index (CDAI) score of greater than or equal to 300; or HBI score greater than or equal to 10; or</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">2.2.\xa0\xa0\xa0\xa0\xa0Patient has extensive small intestine disease affecting more than 50cm of the small intestine; or</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">2.3.\xa0\xa0\xa0\xa0\xa0Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or </span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">2.4.\xa0\xa0\xa0\xa0\xa0Patient has an ileostomy or colostomy and has intestinal inflammation; and </span></p><p><span style=""font-size: 11px;"">\t3.\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0Any of the following: </span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">3.1.\xa0\xa0\xa0\xa0\xa0Patient has tried but had experienced an inadequate response to (including lack of initial response and/or loss of initial response) from prior therapy with immunomodulators and corticosteroids; or</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">3.2.\xa0\xa0\xa0\xa0\xa0Patient has experienced intolerable side effects from immunomodulators and corticosteroids; or</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">3.3.\xa0\xa0\xa0\xa0\xa0Immunomodulators and corticosteroids are contraindicated. </span></p><p><br></p><p><span style=""font-size: 11px;"">\t</span><strong style=""font-size: 11px;"">Renewal –Crohn’s disease – adult </strong></p><p><span style=""font-size: 11px;"">\tApplications only any relevant practitioner. Approvals valid for 2 years.</span></p><p><span style=""font-size: 11px;"">\tBoth:</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">1.\xa0\xa0\xa0\xa0Either</span></p><p class=""ql-indent-2""><span style=""font-size: 11px;"">1.1.\xa0\xa0CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on biological therapy; or HBI score has reduced by 3 points from when patent was initiated on biological therapy; or</span></p><p class=""ql-indent-2""><span style=""font-size: 11px;"">1.2.\xa0\xa0CDAI score is 150 or less, or HBI is 4 or less; or </span></p><p class=""ql-indent-2""><span style=""font-size: 11px;"">1.3.\xa0\xa0The patient has experienced an adequate response to treatment, but CDAI score cannot be assessed; and </span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">2.\xa0\xa0\xa0\xa0Ustekinumab will be used at a dose no greater than 90 mg subcutaneously every 8 weeks.</span></p><p><span style=""font-size: 11px;"">\xa0</span></p><p><span style=""font-size: 11px;"">\t</span><strong style=""font-size: 11px;"">USTEKINUMAB</strong></p><p><span style=""font-size: 11px;"">\t</span><strong style=""font-size: 11px;"">Initiation –Crohn’s disease- children</strong></p><p><span style=""font-size: 11px;"">\tApplications only from a relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 11px;"">\tAll of the following:</span></p><p><span style=""font-size: 11px;"">\t1.\xa0\xa0\xa0Individual has active Crohn’s disease; and </span></p><p><span style=""font-size: 11px;"">\t2.\xa0\xa0\xa0Any of the following: </span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">2.1.\xa0\xa0\xa0\xa0\xa0Patient has Paediatric Crohn’s disease active index (PCDAI) score of greater than or equal to 30; or</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">2.2.\xa0\xa0\xa0\xa0\xa0Patient has extensive small intestine disease; and</span></p><p><span style=""font-size: 11px;"">\t3.\xa0\xa0\xa0Any of the following: </span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">3.1.\xa0\xa0\xa0\xa0\xa0Patient has tried but had experienced an inadequate response to (including lack of initial response and/or loss of initial response) from prior therapy with immunomodulators and corticosteroids; or</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">3.2.\xa0\xa0\xa0\xa0\xa0Patient has experienced intolerable side effects from immunomodulators and corticosteroids; or</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">3.3.\xa0\xa0\xa0\xa0\xa0Immunomodulators and corticosteroids are contraindicated; and</span></p><p><span style=""font-size: 11px;"">\xa0</span></p><p><span style=""font-size: 11px;"">\t</span><strong style=""font-size: 11px;"">Renewal –Crohn’s disease – children</strong></p><p><span style=""font-size: 11px;"">\tApplications only any relevant practitioner. Approvals valid for 2 years.</span></p><p><span style=""font-size: 11px;"">\tAll of the following:</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">1.\xa0\xa0\xa0\xa0Either</span></p><p class=""ql-indent-2""><span style=""font-size: 11px;"">1.1.\xa0\xa0PCDAI score has reduced by 10 points from when the patient was initiated on biological therapy; or</span></p><p class=""ql-indent-2""><span style=""font-size: 11px;"">1.2.\xa0\xa0PCDAI score is 15 or less ;or</span></p><p class=""ql-indent-2""><span style=""font-size: 11px;"">1.3.\xa0\xa0The patient has experienced an adequate response to treatment, but PCDAI score cannot be assessed; and </span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">2.\xa0\xa0\xa0\xa0Ustekinumab will be used at a dose no greater than 90 mg subcutaneously every 8 weeks.</span></p><p><span style=""font-size: 11px;"">\xa0</span><strong style=""font-size: 11px;"">\xa0</strong></p><p><span style=""font-size: 11px;"">\t</span><strong style=""font-size: 11px;"">Initiation –ulcerative colitis</strong></p><p><span style=""font-size: 11px;"">\tApplications from any relevant practitioner. Approvals valid for 6 months for application meeting the following criteria:</span></p><p><span style=""font-size: 11px;"">\tAll of the following:</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">1.\xa0\xa0\xa0\xa0Patient has histologically confirmed ulcerative colitis; and</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">2.\xa0\xa0\xa0\xa0Any of the following: </span></p><p class=""ql-indent-2""><span style=""font-size: 11px;"">2.1.\xa0\xa0Patients has a SCCAI core greater than or equal to 4; or </span></p><p class=""ql-indent-2""><span style=""font-size: 11px;"">2.2.\xa0\xa0Patients PUCAI score is greater than or equal to 20; and </span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">3.\xa0\xa0\xa0\xa0Any of the following </span></p><p class=""ql-indent-2""><span style=""font-size: 11px;"">3.1.\xa0\xa0Patient has tried but had experienced an inadequate response to (including lack of initial response and/or loss of initial response) from prior therapy with immunomodulators and corticosteroids; or</span></p><p class=""ql-indent-2""><span style=""font-size: 11px;"">3.2.\xa0\xa0Patient has experienced intolerable side effects from immunomodulators and corticosteroids; or</span></p><p class=""ql-indent-2""><span style=""font-size: 11px;"">3.3.\xa0\xa0Immunomodulators and corticosteroids are contraindicated.</span></p><p><span style=""font-size: 11px;"">\xa0</span></p><p><span style=""font-size: 11px;"">\t</span><strong style=""font-size: 11px;"">Renewal –ulcerative colitis</strong></p><p><span style=""font-size: 11px;"">\tApplications from any relevant practitioner. Approvals valid for 2 years for any application meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">Both</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">1.\xa0\xa0\xa0\xa0Either: </span></p><p class=""ql-indent-2""><span style=""font-size: 11px;"">1.1.\xa0\xa0The SCCAI score has reduced by 2 points or more from the SCCAI score when the patient was initiated on biological therapy; or </span></p><p class=""ql-indent-2""><span style=""font-size: 11px;"">1.2.\xa0\xa0The PUCAI score has reduced by 10 points or more from the PUCAI score since initiation on biological therapy; and</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">2.\xa0\xa0\xa0\xa0Ustekinumab will be used at a dose no greater than 90 mg subcutaneously every 8 weeks.</span></p><p class=""ql-indent-1""><br></p><p><span style=""font-size: 7pt;"">\xa0</span>In making its recommendation the Committee considered that:</p><ul><li>There was good-quality trial evidence in Crohn’s disease, which provided moderate strength evidence that rates of response and remission were similar for ustekinumab compared to adalimumab in the short term.</li><li>There was a high health need for those with ulcerative colitis that require first-line biologic treatment.</li><li>Ustekinumab did not need to be co-administered with azathioprine, reducing side effects and pill burden.</li><li>Māori and Pacific peoples may experience inequities during diagnosis.</li><li>That it would like to see additional evidence comparing the different inflammatory bowel disease biologics in different lines of treatment.</li></ul>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee <strong>recommended</strong> widening access to Ustekinumab<span style=""color: gray;""> </span>to first-line biologic use for those with Crohn’s disease or ulcerative colitis with a <strong>low priority </strong>subject to the following Special Authority criteria<strong>:</strong>\xa0</p><p><br></p><p><strong style=""font-size: 11px;"">USTEKINUMAB</strong></p><p><span style=""font-size: 11px;"">\t</span><strong style=""font-size: 11px;"">Initiation –Crohn’s disease- adult</strong></p><p><span style=""font-size: 11px;"">\tApplications only from a relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 11px;"">\tAll of the following:</span></p><p><span style=""font-size: 11px;"">\t1.\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0Individual has active Crohn’s disease; and </span></p><p><span style=""font-size: 11px;"">\t2.\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0Any of the following: </span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">2.1.\xa0\xa0\xa0\xa0\xa0Patient has Crohn’s disease active index (CDAI) score of greater than or equal to 300; or HBI score greater than or equal to 10; or</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">2.2.\xa0\xa0\xa0\xa0\xa0Patient has extensive small intestine disease affecting more than 50cm of the small intestine; or</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">2.3.\xa0\xa0\xa0\xa0\xa0Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or </span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">2.4.\xa0\xa0\xa0\xa0\xa0Patient has an ileostomy or colostomy and has intestinal inflammation; and </span></p><p><span style=""font-size: 11px;"">\t3.\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0Any of the following: </span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">3.1.\xa0\xa0\xa0\xa0\xa0Patient has tried but had experienced an inadequate response to (including lack of initial response and/or loss of initial response) from prior therapy with immunomodulators and corticosteroids; or</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">3.2.\xa0\xa0\xa0\xa0\xa0Patient has experienced intolerable side effects from immunomodulators and corticosteroids; or</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">3.3.\xa0\xa0\xa0\xa0\xa0Immunomodulators and corticosteroids are contraindicated. </span></p><p><br></p><p><span style=""font-size: 11px;"">\t</span><strong style=""font-size: 11px;"">Renewal –Crohn’s disease – adult </strong></p><p><span style=""font-size: 11px;"">\tApplications only any relevant practitioner. Approvals valid for 2 years.</span></p><p><span style=""font-size: 11px;"">\tBoth:</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">1.\xa0\xa0\xa0\xa0Either</span></p><p class=""ql-indent-2""><span style=""font-size: 11px;"">1.1.\xa0\xa0CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on biological therapy; or HBI score has reduced by 3 points from when patent was initiated on biological therapy; or</span></p><p class=""ql-indent-2""><span style=""font-size: 11px;"">1.2.\xa0\xa0CDAI score is 150 or less, or HBI is 4 or less; or </span></p><p class=""ql-indent-2""><span style=""font-size: 11px;"">1.3.\xa0\xa0The patient has experienced an adequate response to treatment, but CDAI score cannot be assessed; and </span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">2.\xa0\xa0\xa0\xa0Ustekinumab will be used at a dose no greater than 90 mg subcutaneously every 8 weeks.</span></p><p><span style=""font-size: 11px;"">\xa0</span></p><p><span style=""font-size: 11px;"">\t</span><strong style=""font-size: 11px;"">USTEKINUMAB</strong></p><p><span style=""font-size: 11px;"">\t</span><strong style=""font-size: 11px;"">Initiation –Crohn’s disease- children</strong></p><p><span style=""font-size: 11px;"">\tApplications only from a relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 11px;"">\tAll of the following:</span></p><p><span style=""font-size: 11px;"">\t1.\xa0\xa0\xa0Individual has active Crohn’s disease; and </span></p><p><span style=""font-size: 11px;"">\t2.\xa0\xa0\xa0Any of the following: </span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">2.1.\xa0\xa0\xa0\xa0\xa0Patient has Paediatric Crohn’s disease active index (PCDAI) score of greater than or equal to 30; or</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">2.2.\xa0\xa0\xa0\xa0\xa0Patient has extensive small intestine disease; and</span></p><p><span style=""font-size: 11px;"">\t3.\xa0\xa0\xa0Any of the following: </span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">3.1.\xa0\xa0\xa0\xa0\xa0Patient has tried but had experienced an inadequate response to (including lack of initial response and/or loss of initial response) from prior therapy with immunomodulators and corticosteroids; or</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">3.2.\xa0\xa0\xa0\xa0\xa0Patient has experienced intolerable side effects from immunomodulators and corticosteroids; or</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">3.3.\xa0\xa0\xa0\xa0\xa0Immunomodulators and corticosteroids are contraindicated; and</span></p><p><span style=""font-size: 11px;"">\xa0</span></p><p><span style=""font-size: 11px;"">\t</span><strong style=""font-size: 11px;"">Renewal –Crohn’s disease – children</strong></p><p><span style=""font-size: 11px;"">\tApplications only any relevant practitioner. Approvals valid for 2 years.</span></p><p><span style=""font-size: 11px;"">\tAll of the following:</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">1.\xa0\xa0\xa0\xa0Either</span></p><p class=""ql-indent-2""><span style=""font-size: 11px;"">1.1.\xa0\xa0PCDAI score has reduced by 10 points from when the patient was initiated on biological therapy; or</span></p><p class=""ql-indent-2""><span style=""font-size: 11px;"">1.2.\xa0\xa0PCDAI score is 15 or less ;or</span></p><p class=""ql-indent-2""><span style=""font-size: 11px;"">1.3.\xa0\xa0The patient has experienced an adequate response to treatment, but PCDAI score cannot be assessed; and </span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">2.\xa0\xa0\xa0\xa0Ustekinumab will be used at a dose no greater than 90 mg subcutaneously every 8 weeks.</span></p><p><span style=""font-size: 11px;"">\xa0</span><strong style=""font-size: 11px;"">\xa0</strong></p><p><span style=""font-size: 11px;"">\t</span><strong style=""font-size: 11px;"">Initiation –ulcerative colitis</strong></p><p><span style=""font-size: 11px;"">\tApplications from any relevant practitioner. Approvals valid for 6 months for application meeting the following criteria:</span></p><p><span style=""font-size: 11px;"">\tAll of the following:</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">1.\xa0\xa0\xa0\xa0Patient has histologically confirmed ulcerative colitis; and</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">2.\xa0\xa0\xa0\xa0Any of the following: </span></p><p class=""ql-indent-2""><span style=""font-size: 11px;"">2.1.\xa0\xa0Patients has a SCCAI core greater than or equal to 4; or </span></p><p class=""ql-indent-2""><span style=""font-size: 11px;"">2.2.\xa0\xa0Patients PUCAI score is greater than or equal to 20; and </span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">3.\xa0\xa0\xa0\xa0Any of the following </span></p><p class=""ql-indent-2""><span style=""font-size: 11px;"">3.1.\xa0\xa0Patient has tried but had experienced an inadequate response to (including lack of initial response and/or loss of initial response) from prior therapy with immunomodulators and corticosteroids; or</span></p><p class=""ql-indent-2""><span style=""font-size: 11px;"">3.2.\xa0\xa0Patient has experienced intolerable side effects from immunomodulators and corticosteroids; or</span></p><p class=""ql-indent-2""><span style=""font-size: 11px;"">3.3.\xa0\xa0Immunomodulators and corticosteroids are contraindicated.</span></p><p><span style=""font-size: 11px;"">\xa0</span></p><p><span style=""font-size: 11px;"">\t</span><strong style=""font-size: 11px;"">Renewal –ulcerative colitis</strong></p><p><span style=""font-size: 11px;"">\tApplications from any relevant practitioner. Approvals valid for 2 years for any application meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">Both</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">1.\xa0\xa0\xa0\xa0Either: </span></p><p class=""ql-indent-2""><span style=""font-size: 11px;"">1.1.\xa0\xa0The SCCAI score has reduced by 2 points or more from the SCCAI score when the patient was initiated on biological therapy; or </span></p><p class=""ql-indent-2""><span style=""font-size: 11px;"">1.2.\xa0\xa0The PUCAI score has reduced by 10 points or more from the PUCAI score since initiation on biological therapy; and</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">2.\xa0\xa0\xa0\xa0Ustekinumab will be used at a dose no greater than 90 mg subcutaneously every 8 weeks.</span></p><p class=""ql-indent-1""><br></p><p><span style=""font-size: 7pt;"">\xa0</span>In making its recommendation the Committee considered that:</p><ul><li>There was good-quality trial evidence in Crohn’s disease, which provided moderate strength evidence that rates of response and remission were similar for ustekinumab compared to adalimumab in the short term.</li><li>There was a high health need for those with ulcerative colitis that require first-line biologic treatment.</li><li>Ustekinumab did not need to be co-administered with azathioprine, reducing side effects and pill burden.</li><li>Māori and Pacific peoples may experience inequities during diagnosis.</li><li>That it would like to see additional evidence comparing the different inflammatory bowel disease biologics in different lines of treatment.</li></ul>', 'change': None}, 'Published_Discussion': {'s': '<p><strong style=""font-size: 12px;""><em>Māori impact</em></strong></p><p><span style=""font-size: 12px;"">1.1.\xa0\xa0\xa0\xa0\xa0\xa0\xa0The Committee considered that whilst data suggested that Māori and Pacific peoples were under-represented in the Crohn’s disease or ulcerative colitis population, it is possible that equity issues including access to healthcare specialists may affect diagnosis, and therefore the current data may not accurately reflect the actual incidence and prevalence of inflammatory bowel disease (IBD) in some populations.</span></p><p><em style=""font-size: 12px;"">1.2.\xa0\xa0\xa0\xa0\xa0\xa0\xa0</em><span style=""font-size: 12px;"">The Committee noted that few individuals receiving biologic treatment for ulcerative colitis were Māori (6%) or Pacific peoples (1%) (as of 30 June 2021; PharmHouse data).</span></p><p><strong style=""font-size: 12px;""><em>Background</em></strong></p><p><span style=""font-size: 12px;"">1.3.\xa0\xa0\xa0\xa0\xa0\xa0\xa0The Committee noted that ustekinumab has previously been considered by PTAC for the treatment of Crohn’s disease and ulcerative colitis by the Committee in:</span></p><p class=""ql-indent-1""><span style=""font-size: 12px; font-family: Symbol;"">·</span><span style=""font-size: 12px;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0May 2018 – </span><a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-05.pdf"" target=""_blank"" style=""font-size: 12px;"">Medium Priority</a><span style=""font-size: 12px;""> recommendation for the second line treatment of Crohn’s disease</span></p><p class=""ql-indent-1""><span style=""font-size: 12px; font-family: Symbol;"">·</span><span style=""font-size: 12px;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0February 2019 – reiterated </span><a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2019-02.pdf"" target=""_blank"" style=""font-size: 12px;"">Medium Priority</a><span style=""font-size: 12px;""> recommendation for second-line treatment of Crohn’s disease</span></p><p class=""ql-indent-1""><span style=""font-size: 12px; font-family: Symbol;"">·</span><span style=""font-size: 12px;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0May 2020 – </span><a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000009nuvf/p001516"" target=""_blank"" style=""font-size: 12px;"">Medium Priority</a><span style=""font-size: 12px;""> recommendation for the second-line treatment of ulcerative colitis</span></p><p><span style=""font-size: 12px;"">1.4.\xa0\xa0\xa0\xa0\xa0\xa0\xa0The Committee noted that ustekinumab is currently funded as a second-line biologic for those with Crohn’s disease or ulcerative colitis, and that listing it as a first-line biologic would allow clinicians to use ustekinumab at any line of biologic therapy.</span></p><p><strong style=""font-size: 12px;""><em>Health need</em></strong></p><p><span style=""font-size: 12px;"">1.5.\xa0\xa0\xa0\xa0\xa0\xa0\xa0The Committee noted that historically the crude incidence and prevalence of ulcerative colitis in New Zealand has been estimated to be 7.5 and 145 cases per 100,000 population respectively (</span><a href=""https://pubmed.ncbi.nlm.nih.gov/17012964/"" target=""_blank"" style=""font-size: 12px;"">Gearry et al. Inflamm Bowel Dis. 2006;12:936-43</a><span style=""font-size: 12px;"">), whilst in 2014 the estimated age-standardised incidence rate for Crohn’s disease was 26.4 per 100,000 (</span><a href=""https://pubmed.ncbi.nlm.nih.gov/27482976/"" target=""_blank"" style=""font-size: 12px;"">Su et al. Inflamm Bowel Dis 2016;22: 2238-44</a><span style=""font-size: 12px;"">).</span></p><p><span style=""font-size: 12px;"">1.6.\xa0\xa0\xa0\xa0\xa0\xa0\xa0The Committee noted that there is variability in the presentation of the disease, for example ulcerative colitis presents with continuous areas of inflammation, whilst in Crohn’s disease there are areas of healthy tissue between areas of inflammation. The Committee noted that both conditions are associated with a higher mortality and increased likelihood of being diagnosed with cancer.</span></p><p><span style=""font-size: 12px;"">1.7.\xa0\xa0\xa0\xa0\xa0\xa0\xa0The Committee noted that it has previously considered and discussed the high health need of the population during previous considerations of IBD.</span></p><p><strong style=""font-size: 12px;""><em>Health benefit</em></strong></p><p><span style=""font-size: 12px;"">1.8.\xa0\xa0\xa0\xa0\xa0\xa0\xa0The Committee reviewed data from the SEAVUE trial (</span><a href=""https://pubmed.ncbi.nlm.nih.gov/35691323/"" target=""_blank"" style=""font-size: 12px;"">Sands et al. Lancet.\xa02022;399:2200-11</a><span style=""font-size: 12px;"">), for the treatment of people with moderately to severely active Crohn’s disease who are naïve to biologic agents. The Committee noted that the study, a randomised, double-blind, parallel-group trial, was relevant for the New Zealand population regarding comparison to adalimumab, the inclusion criteria of Crohn’s disease active index (CDAI) 220-450, and the individuals enrolled in the trial being biologically naïve. The Committee noted that the study indicated that 65% of people in the ustekinumab group versus 61% in the adalimumab group were in clinical remission at week 52 (between-group difference 4%, 95% CI -6 to 14; p=0·42), with similar adverse events. The Committee noted that there were lower rates of treatment discontinuation due to adverse events in the ustekinumab treated population compared to adalimumab (6% vs 11% respectively).</span></p><p><span style=""font-size: 12px;"">1.9.\xa0\xa0\xa0\xa0\xa0\xa0\xa0The Committee noted data from the UNIFI trial (</span><a href=""https://pubmed.ncbi.nlm.nih.gov/35239968/"" target=""_blank"" style=""font-size: 12px;"">Abreu et al. J Crohns Colitis. 2022;16:1222-34</a><span style=""font-size: 12px;"">). The Committee noted that this long-term extension study reported data from ustekinumab treatment with 3 years of maintenance in 348 people with ulcerative colitis, as well as a further 284 people who were treated with ustekinumab following unblinding. The Committee noted that in those that were biologic treatment naïve there was persistence of remission, of approximately 70-80%, which the Committee considered was similar to other biologic treatments.\xa0</span></p><p><span style=""font-size: 12px;"">1.10.\xa0\xa0\xa0\xa0The Committee also noted the Onali et al. study (</span><a href=""https://pubmed.ncbi.nlm.nih.gov/35467558/"" target=""_blank"" style=""font-size: 12px;"">Am J Gastroenterol. 2022 1;117:1279-1287</a><span style=""font-size: 12px;"">), an observational retrospective cohort study indirectly comparing the effectiveness of vedolizumab and ustekinumab in those with Crohn’s disease that had progressed despite the use of tumour necrosis factor (TNF)-alpha inhibitors. The Committee noted that this is relevant to the current treatment paradigm in New Zealand following the funding of vedolizumab. The Committee noted that there was no significant difference between the treatments when considering week 6 clinical response (60.1% vs 65.4% ustekinumab, vedolizumab respectively) and week 52 objective remission (29.9% vs 28.4% ustekinumab, vedolizumab respectively).</span></p><p><span style=""font-size: 12px;"">1.11.\xa0\xa0\xa0\xa0The Committee noted a retrospective cohort study by Chien et al (</span><a href=""https://pubmed.ncbi.nlm.nih.gov/34163137/"" target=""_blank"" style=""font-size: 12px;"">Biologics. 2021; 15:237-245</a><span style=""font-size: 12px;"">) observing persistence rates for ustekinumab use in Crohn’s disease in an Australian population. The Committee noted the study reported that 12-month persistence for those receiving ustekinumab as a monotherapy (81.3%, 95% CI 75.5% to 87.6%) was similar to those receiving ustekinumab as a combination therapy with an immunosuppressant (84.9%; CI 77.8% to 92.6%).</span></p><p><span style=""font-size: 12px;"">1.12.\xa0\xa0\xa0\xa0The Committee noted evidence from an observational study by Barclay et al\xa0(</span><a href=""https://pubmed.ncbi.nlm.nih.gov/30091273/"" target=""_blank"" style=""font-size: 12px;"">Intern Med J. 2019;49:513-518</a><span style=""font-size: 12px;"">) suggesting that thiopurine co-administration helped to increase response to biologics by supressing anti-drug antibodies (ADA). The Committee noted half of the study population received concomitant immunosuppressants. The Committee considered that clinicians in New Zealand are favouring a reduction in the use of thiopurines due to the associated risk of adverse events.</span></p><p><span style=""font-size: 12px;"">1.13.\xa0\xa0\xa0\xa0The Committee noted evidence (</span><a href=""https://pubmed.ncbi.nlm.nih.gov/29114832/"" target=""_blank"" style=""font-size: 12px;"">Lemaitre et al, JAMA. 2017;318:1679-86</a><span style=""font-size: 12px;"">) of an increased risk of lymphoma for individuals with IBD who received anti-TNF therapy in combination with a thiopurine (adjusted HR 3.95, 95% CI 1.01-15.5).</span></p><p><span style=""font-size: 12px;"">1.14.\xa0\xa0\xa0\xa0The Committee also noted a meta-analysis of 13 studies (</span><a href=""https://pubmed.ncbi.nlm.nih.gov/30393891/"" target=""_blank"" style=""font-size: 12px;"">Huang et al, J Gastroenterol Hepatol. 2019; 34:507-16</a><span style=""font-size: 12px;"">) reporting an increased risk of skin cancer in people with IBD administered thiopurines (pooled random effects relative risk 1.80, 95% CI 1.14-2.87, p=0.013). The Committee noted that anti-TNF therapies can also increase the risk of skin cancer, and annual skin checks are recommended for this population.</span></p><p><span style=""font-size: 12px;"">1.15.\xa0\xa0\xa0\xa0The Committee also noted the following publications providing evidence for the use of ustekinumab for the treatment of ulcerative colitis or Crohn’s disease:</span></p><p class=""ql-indent-1""><span style=""font-size: 12px; font-family: Symbol;"">·</span><span style=""font-size: 12px;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/34151447/"" target=""_blank"" style=""font-size: 12px;"">Ko et al. Aliment Pharmacol Ther. 2021; 54:292-301</a></p><p class=""ql-indent-1""><span style=""font-size: 12px; font-family: Symbol;"">·</span><span style=""font-size: 12px;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31158271/"" target=""_blank"" style=""font-size: 12px;"">Hanauer et al. J Crohns Colitis. 2020;14:23-32</a></p><p class=""ql-indent-1""><span style=""font-size: 12px; font-family: Symbol;"">·</span><span style=""font-size: 12px;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/35239968/"" target=""_blank"" style=""font-size: 12px;"">Abreu et al, J Crohns Colitis. 2022; 16:1222-1234</a></p><p class=""ql-indent-1""><span style=""font-size: 12px; font-family: Symbol;"">·</span><span style=""font-size: 12px;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/33221330/"" target=""_blank"" style=""font-size: 12px;"">Monin et al, Dig Liver Dis. 2021;53:72-8</a></p><p class=""ql-indent-1""><span style=""font-size: 12px; font-family: Symbol;"">·</span><span style=""font-size: 12px;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/35851799/"" target=""_blank"" style=""font-size: 12px;"">Sedano et al, Inflamm Bowel Dis. 2022 Jul 19;izac149</a></p><p class=""ql-indent-1""><span style=""font-size: 12px; font-family: Symbol;"">·</span><span style=""font-size: 12px;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/35448949/"" target=""_blank"" style=""font-size: 12px;"">Parra et al BMC Gastroenterol. 2022 Apr 21;22:199</a><span style=""font-size: 12px;"">:</span></p><p class=""ql-indent-1""><span style=""font-size: 12px; font-family: Symbol;"">·</span><span style=""font-size: 12px;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/35920382/"" target=""_blank"" style=""font-size: 12px;"">Wong et al, Inflamm Bowel Dis. 2022 3;izac168</a></p><p class=""ql-indent-1""><span style=""font-size: 12px; font-family: Symbol;"">·</span><span style=""font-size: 12px;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;source=web&amp;cd=&amp;cad=rja&amp;uact=8&amp;ved=2ahUKEwijrKTphPj7AhXz6jgGHaoQD5EQFnoECA4QAQ&amp;url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F35917111%2F&amp;usg=AOvVaw18iM_AF-fkhCgeZXGusj1u"" target=""_blank"" style=""font-size: 12px;"">Riviere et al, Inflamm Bowel Dis. 2022 2;izac167</a></p><p class=""ql-indent-1""><span style=""font-size: 12px; font-family: Symbol;"">·</span><span style=""font-size: 12px;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/29920733/"" target=""_blank"" style=""font-size: 12px;"">Singh et al, Aliment Pharmacol Ther. 2018;48:394-409</a></p><p class=""ql-indent-1""><span style=""font-size: 12px; font-family: Symbol;"">·</span><span style=""font-size: 12px;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31960724/"" target=""_blank"" style=""font-size: 12px;"">Welty et al, Curr Med Res Opin. 2020;36:595-606</a></p><p class=""ql-indent-1""><span style=""font-size: 12px; font-family: Symbol;"">·</span><span style=""font-size: 12px;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/34856198/"" target=""_blank"" style=""font-size: 12px;"">Lasa et al, Lancet Gastroenterol Hepatol. 2022;7:161-170</a></p><p class=""ql-indent-1""><span style=""font-size: 12px; color: blue; font-family: Symbol;"">·</span><span style=""font-size: 12px; color: blue;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31945470/"" target=""_blank"" style=""font-size: 12px;"">Singh et al, Clin Gastroenterol Hepatol. 2020;18:2179-91.e6</a></p><p><span style=""color: black; font-size: 12px;"">\xa0</span><span style=""color: rgb(68, 68, 68); font-size: 12px;"">1.16</span><span style=""color: black; font-size: 12px;"">.\xa0\xa0\xa0\xa0</span><span style=""font-size: 12px;"">The Committee considered the evidence to be of moderately high strength and quality with regards to the SEAVUE trial (</span><a href=""https://pubmed.ncbi.nlm.nih.gov/35691323/"" target=""_blank"" style=""font-size: 12px;"">Sands et al, 2022</a><span style=""font-size: 12px;"">). The Committee considered that the available evidence did not suggest a benefit of ustekinumab as a first-line induction or maintenance treatment in Crohn’s disease compared to adalimumab. The Committee considered that there was less certainty about the comparative effectiveness of ustekinumab versus other treatments in ulcerative colitis, given the lack of head-to-head trial evidence. The Committee considered that meta-analysis evidence suggested ustekinumab was likely to provide a benefit in ulcerative colitis versus other agents, particularly adalimumab, though this benefit was less certain.</span></p><p><span style=""font-size: 12px; color: rgb(68, 68, 68);"">1.17</span><span style=""font-size: 12px;"">.\xa0\xa0\xa0\xa0The Committee considered it was likely that ustekinumab would be used as monotherapy for many patients, and that this was likely to result in a reduction in long-term adverse events associated with thiopurine use, including a reduction in risk of developing lymphoma and other cancers. The Committee considered that benefits associated with greater persistence were uncertain given the short duration of the</span></p><p><strong style=""font-size: 12px;""><em>Suitability</em></strong></p><p><span style=""font-size: 12px; color: rgb(68, 68, 68);"">1.18</span><span style=""font-size: 12px;"">.\xa0\xa0\xa0The Committee noted that ustekinumab can be provided as a monotherapy, reducing the need for thiopurines and consequent side effects. The Committee noted that ustekinumab monotherapy also reduced the need for additional blood testing for thiopurine levels and checks for skin cancer. The Committee noted that currently funded biologic therapies (infliximab, adalimumab and vedolizumab) generally require thiopurine co-administration.</span></p><p><span style=""font-size: 12px; color: rgb(68, 68, 68);"">1.19</span><span style=""font-size: 12px;"">.\xa0\xa0The Committee noted that ustekinumab as a monotherapy would offer a reduction in pill burden compared to currently funded biologic therapies, which likely require combination therapy.\xa0</span></p><p><span style=""font-size: 12px; color: rgb(68, 68, 68);"">1.20</span><span style=""font-size: 12px;"">.</span><em style=""font-size: 12px;"">\xa0\xa0\xa0\xa0</em><span style=""font-size: 12px;"">The Committee also noted ustekinumab is available as a prefilled syringe for subcutaneous injection, following the first dose which is administered over the course of a 1-hour intravenous infusion in hospital. The Committee noted that, in comparison, infliximab and vedolizumab must be administered via intravenous infusion in an inpatient setting at weeks 0, 2, and 6, and every 8 weeks thereafter. The Committee considered that the subcutaneous route of administration reduced the travel burden to infusion centres in comparison to infliximab and vedolizumab. The Committee also considered that 8-weekly administration offered an advantage to 2-weekly administration of adalimumab.</span></p><p><strong style=""font-size: 12px;""><em>Cost and savings</em></strong></p><p><span style=""font-size: 12px; color: rgb(68, 68, 68);"">1.21</span><span style=""font-size: 12px;"">.\xa0\xa0\xa0\xa0The Committee noted that the subcutaneous dosing route would reduce the burden on infusion centres in comparison with other biologic drugs, and that it was important to consider those costs and effects on health services in the economic analysis.\xa0</span></p><p><span style=""font-size: 12px; color: rgb(68, 68, 68);"">1.22</span><span style=""font-size: 12px;"">.\xa0\xa0\xa0\xa0The Committee noted that thiopurines concomitantly administered with other biologic therapies would likely result in greater monitoring, including blood tests measuring thiopurine metabolite levels, bone marrow suppression, liver toxicity and annual skin checks. In addition, the Committee considered that there would be a decrease in the number of individuals having severe adverse effects associated with the administration of immunosuppressive therapies, as ustekinumab can be administered as a monotherapy.</span></p><p><span style=""font-size: 12px; color: rgb(68, 68, 68);"">1.23</span><span style=""font-size: 12px;"">.\xa0\xa0\xa0\xa0The Committee considered that uptake of ustekinumab in a first-line setting for Crohn’s disease was likely to be low, given the familiarity of clinicians with adalimumab as a first-line agent. The Committee considered that uptake was likely to be higher for ulcerative colitis, given that first-line adalimumab is less effective in this setting and other biologics</span></p><p><span style=""font-size: 12px;"">require intravenous administration. The Committee considered that it was likely the ulcerative colitis first-line uptake was likely to be in excess of the 25% market share estimate made by Pharmac staff. </span></p><p><strong style=""font-size: 12px;""><em>Summary for assessment </em></strong></p><p><span style=""font-size: 12px; color: rgb(68, 68, 68);"">1.24</span><span style=""font-size: 12px;"">.\xa0\xa0\xa0\xa0The Committee considered that the table below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for ustekinumab if access to ustekinumab were widened to allow use as a first-line biologic treatment for Crohn’s disease and ulcerative colitis. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Committee’s assessment at this time and may differ from that requested by the applicant. The PICO may develop based on new information, additional clinical advice, or further analysis by Pharmac staff.\xa0</span></p><p><img src=""/apptracker/servlet/rtaImage?eid=a0POZ000009MNVi&amp;feoid=00N2P000000YsIc&amp;refid=0EM2P000002mkit"" alt=""image.png""></img></p>', 'fs': '<p><strong style=""font-size: 12px;""><em>Māori impact</em></strong></p><p><span style=""font-size: 12px;"">1.1.\xa0\xa0\xa0\xa0\xa0\xa0\xa0The Committee considered that whilst data suggested that Māori and Pacific peoples were under-represented in the Crohn’s disease or ulcerative colitis population, it is possible that equity issues including access to healthcare specialists may affect diagnosis, and therefore the current data may not accurately reflect the actual incidence and prevalence of inflammatory bowel disease (IBD) in some populations.</span></p><p><em style=""font-size: 12px;"">1.2.\xa0\xa0\xa0\xa0\xa0\xa0\xa0</em><span style=""font-size: 12px;"">The Committee noted that few individuals receiving biologic treatment for ulcerative colitis were Māori (6%) or Pacific peoples (1%) (as of 30 June 2021; PharmHouse data).</span></p><p><strong style=""font-size: 12px;""><em>Background</em></strong></p><p><span style=""font-size: 12px;"">1.3.\xa0\xa0\xa0\xa0\xa0\xa0\xa0The Committee noted that ustekinumab has previously been considered by PTAC for the treatment of Crohn’s disease and ulcerative colitis by the Committee in:</span></p><p class=""ql-indent-1""><span style=""font-size: 12px; font-family: Symbol;"">·</span><span style=""font-size: 12px;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0May 2018 – </span><a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-05.pdf"" target=""_blank"" style=""font-size: 12px;"">Medium Priority</a><span style=""font-size: 12px;""> recommendation for the second line treatment of Crohn’s disease</span></p><p class=""ql-indent-1""><span style=""font-size: 12px; font-family: Symbol;"">·</span><span style=""font-size: 12px;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0February 2019 – reiterated </span><a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2019-02.pdf"" target=""_blank"" style=""font-size: 12px;"">Medium Priority</a><span style=""font-size: 12px;""> recommendation for second-line treatment of Crohn’s disease</span></p><p class=""ql-indent-1""><span style=""font-size: 12px; font-family: Symbol;"">·</span><span style=""font-size: 12px;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0May 2020 – </span><a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000009nuvf/p001516"" target=""_blank"" style=""font-size: 12px;"">Medium Priority</a><span style=""font-size: 12px;""> recommendation for the second-line treatment of ulcerative colitis</span></p><p><span style=""font-size: 12px;"">1.4.\xa0\xa0\xa0\xa0\xa0\xa0\xa0The Committee noted that ustekinumab is currently funded as a second-line biologic for those with Crohn’s disease or ulcerative colitis, and that listing it as a first-line biologic would allow clinicians to use ustekinumab at any line of biologic therapy.</span></p><p><strong style=""font-size: 12px;""><em>Health need</em></strong></p><p><span style=""font-size: 12px;"">1.5.\xa0\xa0\xa0\xa0\xa0\xa0\xa0The Committee noted that historically the crude incidence and prevalence of ulcerative colitis in New Zealand has been estimated to be 7.5 and 145 cases per 100,000 population respectively (</span><a href=""https://pubmed.ncbi.nlm.nih.gov/17012964/"" target=""_blank"" style=""font-size: 12px;"">Gearry et al. Inflamm Bowel Dis. 2006;12:936-43</a><span style=""font-size: 12px;"">), whilst in 2014 the estimated age-standardised incidence rate for Crohn’s disease was 26.4 per 100,000 (</span><a href=""https://pubmed.ncbi.nlm.nih.gov/27482976/"" target=""_blank"" style=""font-size: 12px;"">Su et al. Inflamm Bowel Dis 2016;22: 2238-44</a><span style=""font-size: 12px;"">).</span></p><p><span style=""font-size: 12px;"">1.6.\xa0\xa0\xa0\xa0\xa0\xa0\xa0The Committee noted that there is variability in the presentation of the disease, for example ulcerative colitis presents with continuous areas of inflammation, whilst in Crohn’s disease there are areas of healthy tissue between areas of inflammation. The Committee noted that both conditions are associated with a higher mortality and increased likelihood of being diagnosed with cancer.</span></p><p><span style=""font-size: 12px;"">1.7.\xa0\xa0\xa0\xa0\xa0\xa0\xa0The Committee noted that it has previously considered and discussed the high health need of the population during previous considerations of IBD.</span></p><p><strong style=""font-size: 12px;""><em>Health benefit</em></strong></p><p><span style=""font-size: 12px;"">1.8.\xa0\xa0\xa0\xa0\xa0\xa0\xa0The Committee reviewed data from the SEAVUE trial (</span><a href=""https://pubmed.ncbi.nlm.nih.gov/35691323/"" target=""_blank"" style=""font-size: 12px;"">Sands et al. Lancet.\xa02022;399:2200-11</a><span style=""font-size: 12px;"">), for the treatment of people with moderately to severely active Crohn’s disease who are naïve to biologic agents. The Committee noted that the study, a randomised, double-blind, parallel-group trial, was relevant for the New Zealand population regarding comparison to adalimumab, the inclusion criteria of Crohn’s disease active index (CDAI) 220-450, and the individuals enrolled in the trial being biologically naïve. The Committee noted that the study indicated that 65% of people in the ustekinumab group versus 61% in the adalimumab group were in clinical remission at week 52 (between-group difference 4%, 95% CI -6 to 14; p=0·42), with similar adverse events. The Committee noted that there were lower rates of treatment discontinuation due to adverse events in the ustekinumab treated population compared to adalimumab (6% vs 11% respectively).</span></p><p><span style=""font-size: 12px;"">1.9.\xa0\xa0\xa0\xa0\xa0\xa0\xa0The Committee noted data from the UNIFI trial (</span><a href=""https://pubmed.ncbi.nlm.nih.gov/35239968/"" target=""_blank"" style=""font-size: 12px;"">Abreu et al. J Crohns Colitis. 2022;16:1222-34</a><span style=""font-size: 12px;"">). The Committee noted that this long-term extension study reported data from ustekinumab treatment with 3 years of maintenance in 348 people with ulcerative colitis, as well as a further 284 people who were treated with ustekinumab following unblinding. The Committee noted that in those that were biologic treatment naïve there was persistence of remission, of approximately 70-80%, which the Committee considered was similar to other biologic treatments.\xa0</span></p><p><span style=""font-size: 12px;"">1.10.\xa0\xa0\xa0\xa0The Committee also noted the Onali et al. study (</span><a href=""https://pubmed.ncbi.nlm.nih.gov/35467558/"" target=""_blank"" style=""font-size: 12px;"">Am J Gastroenterol. 2022 1;117:1279-1287</a><span style=""font-size: 12px;"">), an observational retrospective cohort study indirectly comparing the effectiveness of vedolizumab and ustekinumab in those with Crohn’s disease that had progressed despite the use of tumour necrosis factor (TNF)-alpha inhibitors. The Committee noted that this is relevant to the current treatment paradigm in New Zealand following the funding of vedolizumab. The Committee noted that there was no significant difference between the treatments when considering week 6 clinical response (60.1% vs 65.4% ustekinumab, vedolizumab respectively) and week 52 objective remission (29.9% vs 28.4% ustekinumab, vedolizumab respectively).</span></p><p><span style=""font-size: 12px;"">1.11.\xa0\xa0\xa0\xa0The Committee noted a retrospective cohort study by Chien et al (</span><a href=""https://pubmed.ncbi.nlm.nih.gov/34163137/"" target=""_blank"" style=""font-size: 12px;"">Biologics. 2021; 15:237-245</a><span style=""font-size: 12px;"">) observing persistence rates for ustekinumab use in Crohn’s disease in an Australian population. The Committee noted the study reported that 12-month persistence for those receiving ustekinumab as a monotherapy (81.3%, 95% CI 75.5% to 87.6%) was similar to those receiving ustekinumab as a combination therapy with an immunosuppressant (84.9%; CI 77.8% to 92.6%).</span></p><p><span style=""font-size: 12px;"">1.12.\xa0\xa0\xa0\xa0The Committee noted evidence from an observational study by Barclay et al\xa0(</span><a href=""https://pubmed.ncbi.nlm.nih.gov/30091273/"" target=""_blank"" style=""font-size: 12px;"">Intern Med J. 2019;49:513-518</a><span style=""font-size: 12px;"">) suggesting that thiopurine co-administration helped to increase response to biologics by supressing anti-drug antibodies (ADA). The Committee noted half of the study population received concomitant immunosuppressants. The Committee considered that clinicians in New Zealand are favouring a reduction in the use of thiopurines due to the associated risk of adverse events.</span></p><p><span style=""font-size: 12px;"">1.13.\xa0\xa0\xa0\xa0The Committee noted evidence (</span><a href=""https://pubmed.ncbi.nlm.nih.gov/29114832/"" target=""_blank"" style=""font-size: 12px;"">Lemaitre et al, JAMA. 2017;318:1679-86</a><span style=""font-size: 12px;"">) of an increased risk of lymphoma for individuals with IBD who received anti-TNF therapy in combination with a thiopurine (adjusted HR 3.95, 95% CI 1.01-15.5).</span></p><p><span style=""font-size: 12px;"">1.14.\xa0\xa0\xa0\xa0The Committee also noted a meta-analysis of 13 studies (</span><a href=""https://pubmed.ncbi.nlm.nih.gov/30393891/"" target=""_blank"" style=""font-size: 12px;"">Huang et al, J Gastroenterol Hepatol. 2019; 34:507-16</a><span style=""font-size: 12px;"">) reporting an increased risk of skin cancer in people with IBD administered thiopurines (pooled random effects relative risk 1.80, 95% CI 1.14-2.87, p=0.013). The Committee noted that anti-TNF therapies can also increase the risk of skin cancer, and annual skin checks are recommended for this population.</span></p><p><span style=""font-size: 12px;"">1.15.\xa0\xa0\xa0\xa0The Committee also noted the following publications providing evidence for the use of ustekinumab for the treatment of ulcerative colitis or Crohn’s disease:</span></p><p class=""ql-indent-1""><span style=""font-size: 12px; font-family: Symbol;"">·</span><span style=""font-size: 12px;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/34151447/"" target=""_blank"" style=""font-size: 12px;"">Ko et al. Aliment Pharmacol Ther. 2021; 54:292-301</a></p><p class=""ql-indent-1""><span style=""font-size: 12px; font-family: Symbol;"">·</span><span style=""font-size: 12px;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31158271/"" target=""_blank"" style=""font-size: 12px;"">Hanauer et al. J Crohns Colitis. 2020;14:23-32</a></p><p class=""ql-indent-1""><span style=""font-size: 12px; font-family: Symbol;"">·</span><span style=""font-size: 12px;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/35239968/"" target=""_blank"" style=""font-size: 12px;"">Abreu et al, J Crohns Colitis. 2022; 16:1222-1234</a></p><p class=""ql-indent-1""><span style=""font-size: 12px; font-family: Symbol;"">·</span><span style=""font-size: 12px;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/33221330/"" target=""_blank"" style=""font-size: 12px;"">Monin et al, Dig Liver Dis. 2021;53:72-8</a></p><p class=""ql-indent-1""><span style=""font-size: 12px; font-family: Symbol;"">·</span><span style=""font-size: 12px;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/35851799/"" target=""_blank"" style=""font-size: 12px;"">Sedano et al, Inflamm Bowel Dis. 2022 Jul 19;izac149</a></p><p class=""ql-indent-1""><span style=""font-size: 12px; font-family: Symbol;"">·</span><span style=""font-size: 12px;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/35448949/"" target=""_blank"" style=""font-size: 12px;"">Parra et al BMC Gastroenterol. 2022 Apr 21;22:199</a><span style=""font-size: 12px;"">:</span></p><p class=""ql-indent-1""><span style=""font-size: 12px; font-family: Symbol;"">·</span><span style=""font-size: 12px;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/35920382/"" target=""_blank"" style=""font-size: 12px;"">Wong et al, Inflamm Bowel Dis. 2022 3;izac168</a></p><p class=""ql-indent-1""><span style=""font-size: 12px; font-family: Symbol;"">·</span><span style=""font-size: 12px;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;source=web&amp;cd=&amp;cad=rja&amp;uact=8&amp;ved=2ahUKEwijrKTphPj7AhXz6jgGHaoQD5EQFnoECA4QAQ&amp;url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F35917111%2F&amp;usg=AOvVaw18iM_AF-fkhCgeZXGusj1u"" target=""_blank"" style=""font-size: 12px;"">Riviere et al, Inflamm Bowel Dis. 2022 2;izac167</a></p><p class=""ql-indent-1""><span style=""font-size: 12px; font-family: Symbol;"">·</span><span style=""font-size: 12px;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/29920733/"" target=""_blank"" style=""font-size: 12px;"">Singh et al, Aliment Pharmacol Ther. 2018;48:394-409</a></p><p class=""ql-indent-1""><span style=""font-size: 12px; font-family: Symbol;"">·</span><span style=""font-size: 12px;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31960724/"" target=""_blank"" style=""font-size: 12px;"">Welty et al, Curr Med Res Opin. 2020;36:595-606</a></p><p class=""ql-indent-1""><span style=""font-size: 12px; font-family: Symbol;"">·</span><span style=""font-size: 12px;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/34856198/"" target=""_blank"" style=""font-size: 12px;"">Lasa et al, Lancet Gastroenterol Hepatol. 2022;7:161-170</a></p><p class=""ql-indent-1""><span style=""font-size: 12px; color: blue; font-family: Symbol;"">·</span><span style=""font-size: 12px; color: blue;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31945470/"" target=""_blank"" style=""font-size: 12px;"">Singh et al, Clin Gastroenterol Hepatol. 2020;18:2179-91.e6</a></p><p><span style=""color: black; font-size: 12px;"">\xa0</span><span style=""color: rgb(68, 68, 68); font-size: 12px;"">1.16</span><span style=""color: black; font-size: 12px;"">.\xa0\xa0\xa0\xa0</span><span style=""font-size: 12px;"">The Committee considered the evidence to be of moderately high strength and quality with regards to the SEAVUE trial (</span><a href=""https://pubmed.ncbi.nlm.nih.gov/35691323/"" target=""_blank"" style=""font-size: 12px;"">Sands et al, 2022</a><span style=""font-size: 12px;"">). The Committee considered that the available evidence did not suggest a benefit of ustekinumab as a first-line induction or maintenance treatment in Crohn’s disease compared to adalimumab. The Committee considered that there was less certainty about the comparative effectiveness of ustekinumab versus other treatments in ulcerative colitis, given the lack of head-to-head trial evidence. The Committee considered that meta-analysis evidence suggested ustekinumab was likely to provide a benefit in ulcerative colitis versus other agents, particularly adalimumab, though this benefit was less certain.</span></p><p><span style=""font-size: 12px; color: rgb(68, 68, 68);"">1.17</span><span style=""font-size: 12px;"">.\xa0\xa0\xa0\xa0The Committee considered it was likely that ustekinumab would be used as monotherapy for many patients, and that this was likely to result in a reduction in long-term adverse events associated with thiopurine use, including a reduction in risk of developing lymphoma and other cancers. The Committee considered that benefits associated with greater persistence were uncertain given the short duration of the</span></p><p><strong style=""font-size: 12px;""><em>Suitability</em></strong></p><p><span style=""font-size: 12px; color: rgb(68, 68, 68);"">1.18</span><span style=""font-size: 12px;"">.\xa0\xa0\xa0The Committee noted that ustekinumab can be provided as a monotherapy, reducing the need for thiopurines and consequent side effects. The Committee noted that ustekinumab monotherapy also reduced the need for additional blood testing for thiopurine levels and checks for skin cancer. The Committee noted that currently funded biologic therapies (infliximab, adalimumab and vedolizumab) generally require thiopurine co-administration.</span></p><p><span style=""font-size: 12px; color: rgb(68, 68, 68);"">1.19</span><span style=""font-size: 12px;"">.\xa0\xa0The Committee noted that ustekinumab as a monotherapy would offer a reduction in pill burden compared to currently funded biologic therapies, which likely require combination therapy.\xa0</span></p><p><span style=""font-size: 12px; color: rgb(68, 68, 68);"">1.20</span><span style=""font-size: 12px;"">.</span><em style=""font-size: 12px;"">\xa0\xa0\xa0\xa0</em><span style=""font-size: 12px;"">The Committee also noted ustekinumab is available as a prefilled syringe for subcutaneous injection, following the first dose which is administered over the course of a 1-hour intravenous infusion in hospital. The Committee noted that, in comparison, infliximab and vedolizumab must be administered via intravenous infusion in an inpatient setting at weeks 0, 2, and 6, and every 8 weeks thereafter. The Committee considered that the subcutaneous route of administration reduced the travel burden to infusion centres in comparison to infliximab and vedolizumab. The Committee also considered that 8-weekly administration offered an advantage to 2-weekly administration of adalimumab.</span></p><p><strong style=""font-size: 12px;""><em>Cost and savings</em></strong></p><p><span style=""font-size: 12px; color: rgb(68, 68, 68);"">1.21</span><span style=""font-size: 12px;"">.\xa0\xa0\xa0\xa0The Committee noted that the subcutaneous dosing route would reduce the burden on infusion centres in comparison with other biologic drugs, and that it was important to consider those costs and effects on health services in the economic analysis.\xa0</span></p><p><span style=""font-size: 12px; color: rgb(68, 68, 68);"">1.22</span><span style=""font-size: 12px;"">.\xa0\xa0\xa0\xa0The Committee noted that thiopurines concomitantly administered with other biologic therapies would likely result in greater monitoring, including blood tests measuring thiopurine metabolite levels, bone marrow suppression, liver toxicity and annual skin checks. In addition, the Committee considered that there would be a decrease in the number of individuals having severe adverse effects associated with the administration of immunosuppressive therapies, as ustekinumab can be administered as a monotherapy.</span></p><p><span style=""font-size: 12px; color: rgb(68, 68, 68);"">1.23</span><span style=""font-size: 12px;"">.\xa0\xa0\xa0\xa0The Committee considered that uptake of ustekinumab in a first-line setting for Crohn’s disease was likely to be low, given the familiarity of clinicians with adalimumab as a first-line agent. The Committee considered that uptake was likely to be higher for ulcerative colitis, given that first-line adalimumab is less effective in this setting and other biologics</span></p><p><span style=""font-size: 12px;"">require intravenous administration. The Committee considered that it was likely the ulcerative colitis first-line uptake was likely to be in excess of the 25% market share estimate made by Pharmac staff. </span></p><p><strong style=""font-size: 12px;""><em>Summary for assessment </em></strong></p><p><span style=""font-size: 12px; color: rgb(68, 68, 68);"">1.24</span><span style=""font-size: 12px;"">.\xa0\xa0\xa0\xa0The Committee considered that the table below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for ustekinumab if access to ustekinumab were widened to allow use as a first-line biologic treatment for Crohn’s disease and ulcerative colitis. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Committee’s assessment at this time and may differ from that requested by the applicant. The PICO may develop based on new information, additional clinical advice, or further analysis by Pharmac staff.\xa0</span></p><p><img src=""/apptracker/servlet/rtaImage?eid=a0POZ000009MNVi&amp;feoid=00N2P000000YsIc&amp;refid=0EM2P000002mkit"" alt=""image.png""></img></p>', 'change': None}, 'Published_Application': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee reviewed the application for Ustekinumab for first-line biologic treatment of Crohn’s disease and ulcerative colitis.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee reviewed the application for Ustekinumab for first-line biologic treatment of Crohn’s disease and ulcerative colitis.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Low', 'fs': 'Low', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2023', 'fs': 'Jun 2023', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 17 February 2023.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 17 February 2023.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000009MNVi2AO'}, 'Id': 'a0POZ000009MNVi2AO', 'Event_Date__c': '2023-06-21', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 17 February 2023.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Low', 'Formatted_Date__c': 'Jun 2023', 'Published_Recommendation__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee <strong>recommended</strong> widening access to Ustekinumab<span style=""color: gray;""> </span>to first-line biologic use for those with Crohn’s disease or ulcerative colitis with a <strong>low priority </strong>subject to the following Special Authority criteria<strong>:</strong>\xa0</p><p><br></p><p><strong style=""font-size: 11px;"">USTEKINUMAB</strong></p><p><span style=""font-size: 11px;"">\t</span><strong style=""font-size: 11px;"">Initiation –Crohn’s disease- adult</strong></p><p><span style=""font-size: 11px;"">\tApplications only from a relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 11px;"">\tAll of the following:</span></p><p><span style=""font-size: 11px;"">\t1.\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0Individual has active Crohn’s disease; and </span></p><p><span style=""font-size: 11px;"">\t2.\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0Any of the following: </span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">2.1.\xa0\xa0\xa0\xa0\xa0Patient has Crohn’s disease active index (CDAI) score of greater than or equal to 300; or HBI score greater than or equal to 10; or</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">2.2.\xa0\xa0\xa0\xa0\xa0Patient has extensive small intestine disease affecting more than 50cm of the small intestine; or</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">2.3.\xa0\xa0\xa0\xa0\xa0Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or </span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">2.4.\xa0\xa0\xa0\xa0\xa0Patient has an ileostomy or colostomy and has intestinal inflammation; and </span></p><p><span style=""font-size: 11px;"">\t3.\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0Any of the following: </span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">3.1.\xa0\xa0\xa0\xa0\xa0Patient has tried but had experienced an inadequate response to (including lack of initial response and/or loss of initial response) from prior therapy with immunomodulators and corticosteroids; or</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">3.2.\xa0\xa0\xa0\xa0\xa0Patient has experienced intolerable side effects from immunomodulators and corticosteroids; or</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">3.3.\xa0\xa0\xa0\xa0\xa0Immunomodulators and corticosteroids are contraindicated. </span></p><p><br></p><p><span style=""font-size: 11px;"">\t</span><strong style=""font-size: 11px;"">Renewal –Crohn’s disease – adult </strong></p><p><span style=""font-size: 11px;"">\tApplications only any relevant practitioner. Approvals valid for 2 years.</span></p><p><span style=""font-size: 11px;"">\tBoth:</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">1.\xa0\xa0\xa0\xa0Either</span></p><p class=""ql-indent-2""><span style=""font-size: 11px;"">1.1.\xa0\xa0CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on biological therapy; or HBI score has reduced by 3 points from when patent was initiated on biological therapy; or</span></p><p class=""ql-indent-2""><span style=""font-size: 11px;"">1.2.\xa0\xa0CDAI score is 150 or less, or HBI is 4 or less; or </span></p><p class=""ql-indent-2""><span style=""font-size: 11px;"">1.3.\xa0\xa0The patient has experienced an adequate response to treatment, but CDAI score cannot be assessed; and </span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">2.\xa0\xa0\xa0\xa0Ustekinumab will be used at a dose no greater than 90 mg subcutaneously every 8 weeks.</span></p><p><span style=""font-size: 11px;"">\xa0</span></p><p><span style=""font-size: 11px;"">\t</span><strong style=""font-size: 11px;"">USTEKINUMAB</strong></p><p><span style=""font-size: 11px;"">\t</span><strong style=""font-size: 11px;"">Initiation –Crohn’s disease- children</strong></p><p><span style=""font-size: 11px;"">\tApplications only from a relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 11px;"">\tAll of the following:</span></p><p><span style=""font-size: 11px;"">\t1.\xa0\xa0\xa0Individual has active Crohn’s disease; and </span></p><p><span style=""font-size: 11px;"">\t2.\xa0\xa0\xa0Any of the following: </span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">2.1.\xa0\xa0\xa0\xa0\xa0Patient has Paediatric Crohn’s disease active index (PCDAI) score of greater than or equal to 30; or</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">2.2.\xa0\xa0\xa0\xa0\xa0Patient has extensive small intestine disease; and</span></p><p><span style=""font-size: 11px;"">\t3.\xa0\xa0\xa0Any of the following: </span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">3.1.\xa0\xa0\xa0\xa0\xa0Patient has tried but had experienced an inadequate response to (including lack of initial response and/or loss of initial response) from prior therapy with immunomodulators and corticosteroids; or</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">3.2.\xa0\xa0\xa0\xa0\xa0Patient has experienced intolerable side effects from immunomodulators and corticosteroids; or</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">3.3.\xa0\xa0\xa0\xa0\xa0Immunomodulators and corticosteroids are contraindicated; and</span></p><p><span style=""font-size: 11px;"">\xa0</span></p><p><span style=""font-size: 11px;"">\t</span><strong style=""font-size: 11px;"">Renewal –Crohn’s disease – children</strong></p><p><span style=""font-size: 11px;"">\tApplications only any relevant practitioner. Approvals valid for 2 years.</span></p><p><span style=""font-size: 11px;"">\tAll of the following:</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">1.\xa0\xa0\xa0\xa0Either</span></p><p class=""ql-indent-2""><span style=""font-size: 11px;"">1.1.\xa0\xa0PCDAI score has reduced by 10 points from when the patient was initiated on biological therapy; or</span></p><p class=""ql-indent-2""><span style=""font-size: 11px;"">1.2.\xa0\xa0PCDAI score is 15 or less ;or</span></p><p class=""ql-indent-2""><span style=""font-size: 11px;"">1.3.\xa0\xa0The patient has experienced an adequate response to treatment, but PCDAI score cannot be assessed; and </span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">2.\xa0\xa0\xa0\xa0Ustekinumab will be used at a dose no greater than 90 mg subcutaneously every 8 weeks.</span></p><p><span style=""font-size: 11px;"">\xa0</span><strong style=""font-size: 11px;"">\xa0</strong></p><p><span style=""font-size: 11px;"">\t</span><strong style=""font-size: 11px;"">Initiation –ulcerative colitis</strong></p><p><span style=""font-size: 11px;"">\tApplications from any relevant practitioner. Approvals valid for 6 months for application meeting the following criteria:</span></p><p><span style=""font-size: 11px;"">\tAll of the following:</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">1.\xa0\xa0\xa0\xa0Patient has histologically confirmed ulcerative colitis; and</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">2.\xa0\xa0\xa0\xa0Any of the following: </span></p><p class=""ql-indent-2""><span style=""font-size: 11px;"">2.1.\xa0\xa0Patients has a SCCAI core greater than or equal to 4; or </span></p><p class=""ql-indent-2""><span style=""font-size: 11px;"">2.2.\xa0\xa0Patients PUCAI score is greater than or equal to 20; and </span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">3.\xa0\xa0\xa0\xa0Any of the following </span></p><p class=""ql-indent-2""><span style=""font-size: 11px;"">3.1.\xa0\xa0Patient has tried but had experienced an inadequate response to (including lack of initial response and/or loss of initial response) from prior therapy with immunomodulators and corticosteroids; or</span></p><p class=""ql-indent-2""><span style=""font-size: 11px;"">3.2.\xa0\xa0Patient has experienced intolerable side effects from immunomodulators and corticosteroids; or</span></p><p class=""ql-indent-2""><span style=""font-size: 11px;"">3.3.\xa0\xa0Immunomodulators and corticosteroids are contraindicated.</span></p><p><span style=""font-size: 11px;"">\xa0</span></p><p><span style=""font-size: 11px;"">\t</span><strong style=""font-size: 11px;"">Renewal –ulcerative colitis</strong></p><p><span style=""font-size: 11px;"">\tApplications from any relevant practitioner. Approvals valid for 2 years for any application meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">Both</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">1.\xa0\xa0\xa0\xa0Either: </span></p><p class=""ql-indent-2""><span style=""font-size: 11px;"">1.1.\xa0\xa0The SCCAI score has reduced by 2 points or more from the SCCAI score when the patient was initiated on biological therapy; or </span></p><p class=""ql-indent-2""><span style=""font-size: 11px;"">1.2.\xa0\xa0The PUCAI score has reduced by 10 points or more from the PUCAI score since initiation on biological therapy; and</span></p><p class=""ql-indent-1""><span style=""font-size: 11px;"">2.\xa0\xa0\xa0\xa0Ustekinumab will be used at a dose no greater than 90 mg subcutaneously every 8 weeks.</span></p><p class=""ql-indent-1""><br></p><p><span style=""font-size: 7pt;"">\xa0</span>In making its recommendation the Committee considered that:</p><ul><li>There was good-quality trial evidence in Crohn’s disease, which provided moderate strength evidence that rates of response and remission were similar for ustekinumab compared to adalimumab in the short term.</li><li>There was a high health need for those with ulcerative colitis that require first-line biologic treatment.</li><li>Ustekinumab did not need to be co-administered with azathioprine, reducing side effects and pill burden.</li><li>Māori and Pacific peoples may experience inequities during diagnosis.</li><li>That it would like to see additional evidence comparing the different inflammatory bowel disease biologics in different lines of treatment.</li></ul>', 'Published_Application__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee reviewed the application for Ustekinumab for first-line biologic treatment of Crohn’s disease and ulcerative colitis.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'Published_Discussion__c': '<p><strong style=""font-size: 12px;""><em>Māori impact</em></strong></p><p><span style=""font-size: 12px;"">1.1.\xa0\xa0\xa0\xa0\xa0\xa0\xa0The Committee considered that whilst data suggested that Māori and Pacific peoples were under-represented in the Crohn’s disease or ulcerative colitis population, it is possible that equity issues including access to healthcare specialists may affect diagnosis, and therefore the current data may not accurately reflect the actual incidence and prevalence of inflammatory bowel disease (IBD) in some populations.</span></p><p><em style=""font-size: 12px;"">1.2.\xa0\xa0\xa0\xa0\xa0\xa0\xa0</em><span style=""font-size: 12px;"">The Committee noted that few individuals receiving biologic treatment for ulcerative colitis were Māori (6%) or Pacific peoples (1%) (as of 30 June 2021; PharmHouse data).</span></p><p><strong style=""font-size: 12px;""><em>Background</em></strong></p><p><span style=""font-size: 12px;"">1.3.\xa0\xa0\xa0\xa0\xa0\xa0\xa0The Committee noted that ustekinumab has previously been considered by PTAC for the treatment of Crohn’s disease and ulcerative colitis by the Committee in:</span></p><p class=""ql-indent-1""><span style=""font-size: 12px; font-family: Symbol;"">·</span><span style=""font-size: 12px;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0May 2018 – </span><a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-05.pdf"" target=""_blank"" style=""font-size: 12px;"">Medium Priority</a><span style=""font-size: 12px;""> recommendation for the second line treatment of Crohn’s disease</span></p><p class=""ql-indent-1""><span style=""font-size: 12px; font-family: Symbol;"">·</span><span style=""font-size: 12px;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0February 2019 – reiterated </span><a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2019-02.pdf"" target=""_blank"" style=""font-size: 12px;"">Medium Priority</a><span style=""font-size: 12px;""> recommendation for second-line treatment of Crohn’s disease</span></p><p class=""ql-indent-1""><span style=""font-size: 12px; font-family: Symbol;"">·</span><span style=""font-size: 12px;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0May 2020 – </span><a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000009nuvf/p001516"" target=""_blank"" style=""font-size: 12px;"">Medium Priority</a><span style=""font-size: 12px;""> recommendation for the second-line treatment of ulcerative colitis</span></p><p><span style=""font-size: 12px;"">1.4.\xa0\xa0\xa0\xa0\xa0\xa0\xa0The Committee noted that ustekinumab is currently funded as a second-line biologic for those with Crohn’s disease or ulcerative colitis, and that listing it as a first-line biologic would allow clinicians to use ustekinumab at any line of biologic therapy.</span></p><p><strong style=""font-size: 12px;""><em>Health need</em></strong></p><p><span style=""font-size: 12px;"">1.5.\xa0\xa0\xa0\xa0\xa0\xa0\xa0The Committee noted that historically the crude incidence and prevalence of ulcerative colitis in New Zealand has been estimated to be 7.5 and 145 cases per 100,000 population respectively (</span><a href=""https://pubmed.ncbi.nlm.nih.gov/17012964/"" target=""_blank"" style=""font-size: 12px;"">Gearry et al. Inflamm Bowel Dis. 2006;12:936-43</a><span style=""font-size: 12px;"">), whilst in 2014 the estimated age-standardised incidence rate for Crohn’s disease was 26.4 per 100,000 (</span><a href=""https://pubmed.ncbi.nlm.nih.gov/27482976/"" target=""_blank"" style=""font-size: 12px;"">Su et al. Inflamm Bowel Dis 2016;22: 2238-44</a><span style=""font-size: 12px;"">).</span></p><p><span style=""font-size: 12px;"">1.6.\xa0\xa0\xa0\xa0\xa0\xa0\xa0The Committee noted that there is variability in the presentation of the disease, for example ulcerative colitis presents with continuous areas of inflammation, whilst in Crohn’s disease there are areas of healthy tissue between areas of inflammation. The Committee noted that both conditions are associated with a higher mortality and increased likelihood of being diagnosed with cancer.</span></p><p><span style=""font-size: 12px;"">1.7.\xa0\xa0\xa0\xa0\xa0\xa0\xa0The Committee noted that it has previously considered and discussed the high health need of the population during previous considerations of IBD.</span></p><p><strong style=""font-size: 12px;""><em>Health benefit</em></strong></p><p><span style=""font-size: 12px;"">1.8.\xa0\xa0\xa0\xa0\xa0\xa0\xa0The Committee reviewed data from the SEAVUE trial (</span><a href=""https://pubmed.ncbi.nlm.nih.gov/35691323/"" target=""_blank"" style=""font-size: 12px;"">Sands et al. Lancet.\xa02022;399:2200-11</a><span style=""font-size: 12px;"">), for the treatment of people with moderately to severely active Crohn’s disease who are naïve to biologic agents. The Committee noted that the study, a randomised, double-blind, parallel-group trial, was relevant for the New Zealand population regarding comparison to adalimumab, the inclusion criteria of Crohn’s disease active index (CDAI) 220-450, and the individuals enrolled in the trial being biologically naïve. The Committee noted that the study indicated that 65% of people in the ustekinumab group versus 61% in the adalimumab group were in clinical remission at week 52 (between-group difference 4%, 95% CI -6 to 14; p=0·42), with similar adverse events. The Committee noted that there were lower rates of treatment discontinuation due to adverse events in the ustekinumab treated population compared to adalimumab (6% vs 11% respectively).</span></p><p><span style=""font-size: 12px;"">1.9.\xa0\xa0\xa0\xa0\xa0\xa0\xa0The Committee noted data from the UNIFI trial (</span><a href=""https://pubmed.ncbi.nlm.nih.gov/35239968/"" target=""_blank"" style=""font-size: 12px;"">Abreu et al. J Crohns Colitis. 2022;16:1222-34</a><span style=""font-size: 12px;"">). The Committee noted that this long-term extension study reported data from ustekinumab treatment with 3 years of maintenance in 348 people with ulcerative colitis, as well as a further 284 people who were treated with ustekinumab following unblinding. The Committee noted that in those that were biologic treatment naïve there was persistence of remission, of approximately 70-80%, which the Committee considered was similar to other biologic treatments.\xa0</span></p><p><span style=""font-size: 12px;"">1.10.\xa0\xa0\xa0\xa0The Committee also noted the Onali et al. study (</span><a href=""https://pubmed.ncbi.nlm.nih.gov/35467558/"" target=""_blank"" style=""font-size: 12px;"">Am J Gastroenterol. 2022 1;117:1279-1287</a><span style=""font-size: 12px;"">), an observational retrospective cohort study indirectly comparing the effectiveness of vedolizumab and ustekinumab in those with Crohn’s disease that had progressed despite the use of tumour necrosis factor (TNF)-alpha inhibitors. The Committee noted that this is relevant to the current treatment paradigm in New Zealand following the funding of vedolizumab. The Committee noted that there was no significant difference between the treatments when considering week 6 clinical response (60.1% vs 65.4% ustekinumab, vedolizumab respectively) and week 52 objective remission (29.9% vs 28.4% ustekinumab, vedolizumab respectively).</span></p><p><span style=""font-size: 12px;"">1.11.\xa0\xa0\xa0\xa0The Committee noted a retrospective cohort study by Chien et al (</span><a href=""https://pubmed.ncbi.nlm.nih.gov/34163137/"" target=""_blank"" style=""font-size: 12px;"">Biologics. 2021; 15:237-245</a><span style=""font-size: 12px;"">) observing persistence rates for ustekinumab use in Crohn’s disease in an Australian population. The Committee noted the study reported that 12-month persistence for those receiving ustekinumab as a monotherapy (81.3%, 95% CI 75.5% to 87.6%) was similar to those receiving ustekinumab as a combination therapy with an immunosuppressant (84.9%; CI 77.8% to 92.6%).</span></p><p><span style=""font-size: 12px;"">1.12.\xa0\xa0\xa0\xa0The Committee noted evidence from an observational study by Barclay et al\xa0(</span><a href=""https://pubmed.ncbi.nlm.nih.gov/30091273/"" target=""_blank"" style=""font-size: 12px;"">Intern Med J. 2019;49:513-518</a><span style=""font-size: 12px;"">) suggesting that thiopurine co-administration helped to increase response to biologics by supressing anti-drug antibodies (ADA). The Committee noted half of the study population received concomitant immunosuppressants. The Committee considered that clinicians in New Zealand are favouring a reduction in the use of thiopurines due to the associated risk of adverse events.</span></p><p><span style=""font-size: 12px;"">1.13.\xa0\xa0\xa0\xa0The Committee noted evidence (</span><a href=""https://pubmed.ncbi.nlm.nih.gov/29114832/"" target=""_blank"" style=""font-size: 12px;"">Lemaitre et al, JAMA. 2017;318:1679-86</a><span style=""font-size: 12px;"">) of an increased risk of lymphoma for individuals with IBD who received anti-TNF therapy in combination with a thiopurine (adjusted HR 3.95, 95% CI 1.01-15.5).</span></p><p><span style=""font-size: 12px;"">1.14.\xa0\xa0\xa0\xa0The Committee also noted a meta-analysis of 13 studies (</span><a href=""https://pubmed.ncbi.nlm.nih.gov/30393891/"" target=""_blank"" style=""font-size: 12px;"">Huang et al, J Gastroenterol Hepatol. 2019; 34:507-16</a><span style=""font-size: 12px;"">) reporting an increased risk of skin cancer in people with IBD administered thiopurines (pooled random effects relative risk 1.80, 95% CI 1.14-2.87, p=0.013). The Committee noted that anti-TNF therapies can also increase the risk of skin cancer, and annual skin checks are recommended for this population.</span></p><p><span style=""font-size: 12px;"">1.15.\xa0\xa0\xa0\xa0The Committee also noted the following publications providing evidence for the use of ustekinumab for the treatment of ulcerative colitis or Crohn’s disease:</span></p><p class=""ql-indent-1""><span style=""font-size: 12px; font-family: Symbol;"">·</span><span style=""font-size: 12px;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/34151447/"" target=""_blank"" style=""font-size: 12px;"">Ko et al. Aliment Pharmacol Ther. 2021; 54:292-301</a></p><p class=""ql-indent-1""><span style=""font-size: 12px; font-family: Symbol;"">·</span><span style=""font-size: 12px;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31158271/"" target=""_blank"" style=""font-size: 12px;"">Hanauer et al. J Crohns Colitis. 2020;14:23-32</a></p><p class=""ql-indent-1""><span style=""font-size: 12px; font-family: Symbol;"">·</span><span style=""font-size: 12px;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/35239968/"" target=""_blank"" style=""font-size: 12px;"">Abreu et al, J Crohns Colitis. 2022; 16:1222-1234</a></p><p class=""ql-indent-1""><span style=""font-size: 12px; font-family: Symbol;"">·</span><span style=""font-size: 12px;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/33221330/"" target=""_blank"" style=""font-size: 12px;"">Monin et al, Dig Liver Dis. 2021;53:72-8</a></p><p class=""ql-indent-1""><span style=""font-size: 12px; font-family: Symbol;"">·</span><span style=""font-size: 12px;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/35851799/"" target=""_blank"" style=""font-size: 12px;"">Sedano et al, Inflamm Bowel Dis. 2022 Jul 19;izac149</a></p><p class=""ql-indent-1""><span style=""font-size: 12px; font-family: Symbol;"">·</span><span style=""font-size: 12px;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/35448949/"" target=""_blank"" style=""font-size: 12px;"">Parra et al BMC Gastroenterol. 2022 Apr 21;22:199</a><span style=""font-size: 12px;"">:</span></p><p class=""ql-indent-1""><span style=""font-size: 12px; font-family: Symbol;"">·</span><span style=""font-size: 12px;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/35920382/"" target=""_blank"" style=""font-size: 12px;"">Wong et al, Inflamm Bowel Dis. 2022 3;izac168</a></p><p class=""ql-indent-1""><span style=""font-size: 12px; font-family: Symbol;"">·</span><span style=""font-size: 12px;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;source=web&amp;cd=&amp;cad=rja&amp;uact=8&amp;ved=2ahUKEwijrKTphPj7AhXz6jgGHaoQD5EQFnoECA4QAQ&amp;url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F35917111%2F&amp;usg=AOvVaw18iM_AF-fkhCgeZXGusj1u"" target=""_blank"" style=""font-size: 12px;"">Riviere et al, Inflamm Bowel Dis. 2022 2;izac167</a></p><p class=""ql-indent-1""><span style=""font-size: 12px; font-family: Symbol;"">·</span><span style=""font-size: 12px;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/29920733/"" target=""_blank"" style=""font-size: 12px;"">Singh et al, Aliment Pharmacol Ther. 2018;48:394-409</a></p><p class=""ql-indent-1""><span style=""font-size: 12px; font-family: Symbol;"">·</span><span style=""font-size: 12px;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31960724/"" target=""_blank"" style=""font-size: 12px;"">Welty et al, Curr Med Res Opin. 2020;36:595-606</a></p><p class=""ql-indent-1""><span style=""font-size: 12px; font-family: Symbol;"">·</span><span style=""font-size: 12px;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/34856198/"" target=""_blank"" style=""font-size: 12px;"">Lasa et al, Lancet Gastroenterol Hepatol. 2022;7:161-170</a></p><p class=""ql-indent-1""><span style=""font-size: 12px; color: blue; font-family: Symbol;"">·</span><span style=""font-size: 12px; color: blue;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31945470/"" target=""_blank"" style=""font-size: 12px;"">Singh et al, Clin Gastroenterol Hepatol. 2020;18:2179-91.e6</a></p><p><span style=""color: black; font-size: 12px;"">\xa0</span><span style=""color: rgb(68, 68, 68); font-size: 12px;"">1.16</span><span style=""color: black; font-size: 12px;"">.\xa0\xa0\xa0\xa0</span><span style=""font-size: 12px;"">The Committee considered the evidence to be of moderately high strength and quality with regards to the SEAVUE trial (</span><a href=""https://pubmed.ncbi.nlm.nih.gov/35691323/"" target=""_blank"" style=""font-size: 12px;"">Sands et al, 2022</a><span style=""font-size: 12px;"">). The Committee considered that the available evidence did not suggest a benefit of ustekinumab as a first-line induction or maintenance treatment in Crohn’s disease compared to adalimumab. The Committee considered that there was less certainty about the comparative effectiveness of ustekinumab versus other treatments in ulcerative colitis, given the lack of head-to-head trial evidence. The Committee considered that meta-analysis evidence suggested ustekinumab was likely to provide a benefit in ulcerative colitis versus other agents, particularly adalimumab, though this benefit was less certain.</span></p><p><span style=""font-size: 12px; color: rgb(68, 68, 68);"">1.17</span><span style=""font-size: 12px;"">.\xa0\xa0\xa0\xa0The Committee considered it was likely that ustekinumab would be used as monotherapy for many patients, and that this was likely to result in a reduction in long-term adverse events associated with thiopurine use, including a reduction in risk of developing lymphoma and other cancers. The Committee considered that benefits associated with greater persistence were uncertain given the short duration of the</span></p><p><strong style=""font-size: 12px;""><em>Suitability</em></strong></p><p><span style=""font-size: 12px; color: rgb(68, 68, 68);"">1.18</span><span style=""font-size: 12px;"">.\xa0\xa0\xa0The Committee noted that ustekinumab can be provided as a monotherapy, reducing the need for thiopurines and consequent side effects. The Committee noted that ustekinumab monotherapy also reduced the need for additional blood testing for thiopurine levels and checks for skin cancer. The Committee noted that currently funded biologic therapies (infliximab, adalimumab and vedolizumab) generally require thiopurine co-administration.</span></p><p><span style=""font-size: 12px; color: rgb(68, 68, 68);"">1.19</span><span style=""font-size: 12px;"">.\xa0\xa0The Committee noted that ustekinumab as a monotherapy would offer a reduction in pill burden compared to currently funded biologic therapies, which likely require combination therapy.\xa0</span></p><p><span style=""font-size: 12px; color: rgb(68, 68, 68);"">1.20</span><span style=""font-size: 12px;"">.</span><em style=""font-size: 12px;"">\xa0\xa0\xa0\xa0</em><span style=""font-size: 12px;"">The Committee also noted ustekinumab is available as a prefilled syringe for subcutaneous injection, following the first dose which is administered over the course of a 1-hour intravenous infusion in hospital. The Committee noted that, in comparison, infliximab and vedolizumab must be administered via intravenous infusion in an inpatient setting at weeks 0, 2, and 6, and every 8 weeks thereafter. The Committee considered that the subcutaneous route of administration reduced the travel burden to infusion centres in comparison to infliximab and vedolizumab. The Committee also considered that 8-weekly administration offered an advantage to 2-weekly administration of adalimumab.</span></p><p><strong style=""font-size: 12px;""><em>Cost and savings</em></strong></p><p><span style=""font-size: 12px; color: rgb(68, 68, 68);"">1.21</span><span style=""font-size: 12px;"">.\xa0\xa0\xa0\xa0The Committee noted that the subcutaneous dosing route would reduce the burden on infusion centres in comparison with other biologic drugs, and that it was important to consider those costs and effects on health services in the economic analysis.\xa0</span></p><p><span style=""font-size: 12px; color: rgb(68, 68, 68);"">1.22</span><span style=""font-size: 12px;"">.\xa0\xa0\xa0\xa0The Committee noted that thiopurines concomitantly administered with other biologic therapies would likely result in greater monitoring, including blood tests measuring thiopurine metabolite levels, bone marrow suppression, liver toxicity and annual skin checks. In addition, the Committee considered that there would be a decrease in the number of individuals having severe adverse effects associated with the administration of immunosuppressive therapies, as ustekinumab can be administered as a monotherapy.</span></p><p><span style=""font-size: 12px; color: rgb(68, 68, 68);"">1.23</span><span style=""font-size: 12px;"">.\xa0\xa0\xa0\xa0The Committee considered that uptake of ustekinumab in a first-line setting for Crohn’s disease was likely to be low, given the familiarity of clinicians with adalimumab as a first-line agent. The Committee considered that uptake was likely to be higher for ulcerative colitis, given that first-line adalimumab is less effective in this setting and other biologics</span></p><p><span style=""font-size: 12px;"">require intravenous administration. The Committee considered that it was likely the ulcerative colitis first-line uptake was likely to be in excess of the 25% market share estimate made by Pharmac staff. </span></p><p><strong style=""font-size: 12px;""><em>Summary for assessment </em></strong></p><p><span style=""font-size: 12px; color: rgb(68, 68, 68);"">1.24</span><span style=""font-size: 12px;"">.\xa0\xa0\xa0\xa0The Committee considered that the table below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for ustekinumab if access to ustekinumab were widened to allow use as a first-line biologic treatment for Crohn’s disease and ulcerative colitis. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Committee’s assessment at this time and may differ from that requested by the applicant. The PICO may develop based on new information, additional clinical advice, or further analysis by Pharmac staff.\xa0</span></p><p><img src=""/apptracker/servlet/rtaImage?eid=a0POZ000009MNVi&amp;feoid=00N2P000000YsIc&amp;refid=0EM2P000002mkit"" alt=""image.png""></img></p>', 'Status_History__c': 'a132P000000Egl7QAC'}, 'change': None}]",Dec 2022,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2023', 'fs': 'Jun 2023', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000009MNVh2AO'}, 'Id': 'a0POZ000009MNVh2AO', 'Event_Date__c': '2023-06-21', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Jun 2023', 'Status_History__c': 'a132P000000EidpQAC'}, 'change': None}]",Jun 2023,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,,,False,False
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,,,False,False
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,,,False,False
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,,,False,False
